Kymera at Goldman Sachs Conference: Pioneering Oral Protein Degraders

Kymera Therapeutics presented at the Goldman Sachs Healthcare Conference, highlighting its oral protein degrader programs, particularly the STAT6 program (KT-621) for immunology, which aims to be an oral alternative to biologics like Dupixent. Phase 1 data for KT-621 showed significant STAT6 degradation and a strong safety profile, leading to a Phase 1b study in atopic dermatitis, with Phase 2b studies planned for late this year or early next year. The company also noted a $20 million milestone payment from Sanofi for the IRAK4 program, which is progressing through Phase 2b studies managed by Sanofi, with Kymera retaining an opt-in option before Phase 3.

Analysis

Kymera Therapeutics (NASDAQ:KYMR) detailed significant advancements in its oral protein degrader pipeline at the Goldman Sachs 46th Annual Global Healthcare Conference, primarily focusing on its STAT6 program, KT-621, for immunology. Phase 1 data for KT-621 were promising, showing over 90% STAT6 degradation, with complete degradation observed at doses of 50mg and above, alongside a strong safety profile described as "placebo-like" and encouraging biomarker responses (TARC, biotoxin-three) in healthy volunteers. These results have supported the initiation of a Phase 1b study in atopic dermatitis patients, focusing on biomarker impact with data expected later in 2025, and pave the way for larger, placebo-controlled Phase 2b studies planned for late 2025 or early 2026. Kymera aims for KT-621 to serve as an oral alternative to biologics like Dupixent, potentially offering biologic-like efficacy. On the financial front, the company reported a $20 million milestone payment from Sanofi concerning their partnered IRAK4 program, which Sanofi is advancing through Phase 2b studies in hidradenitis suppurativa and atopic dermatitis; Kymera retains an option to co-develop and co-commercialize IRAK4 globally before Phase 3, contingent on strategic resource allocation. Additionally, Kymera is broadening its immunology portfolio with its IRF5 degrader program (KT-253, referred to as 579 in the transcript) targeting lupus and other interferon-mediated pathologies, with a Phase 1 study anticipated in early 2026. The company's strategy involves potential partnerships after Phase 2b data, with the overarching goal of becoming a global commercial-stage biopharmaceutical company.

Key Decisions for Investors

• Investors should closely monitor the upcoming Phase 1b data for KT-621 in atopic dermatitis, anticipated later in 2025, as positive biomarker outcomes in patients will be a key validation for its potential as an 'oral Dupixent' and will significantly de-risk its progression to Phase 2b trials.
• Carefully evaluate the progress of the Sanofi-led IRAK4 program through its Phase 2b studies and Kymera's subsequent decision regarding the pre-Phase 3 opt-in, considering the financial commitment against the prioritization of the wholly-owned and highly promising KT-621 program.
• Consider the substantial long-term market opportunity for KT-621 if it successfully achieves its targeted biologic-like oral profile, while also factoring in the inherent clinical development risks, the company's capital expenditure for advancing multiple programs including the IRF5 asset, and its articulated partnership strategy post-Phase 2 proof-of-concept.